JP2010504314A - リファキシミン - Google Patents

リファキシミン Download PDF

Info

Publication number
JP2010504314A
JP2010504314A JP2009528789A JP2009528789A JP2010504314A JP 2010504314 A JP2010504314 A JP 2010504314A JP 2009528789 A JP2009528789 A JP 2009528789A JP 2009528789 A JP2009528789 A JP 2009528789A JP 2010504314 A JP2010504314 A JP 2010504314A
Authority
JP
Japan
Prior art keywords
rifaximin
water
amorphous
solvent
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009528789A
Other languages
English (en)
Japanese (ja)
Inventor
ラオ、ダルマラジ・ラマチャンドラ
カンカン、ラジェンドラ・ナラヤンラオ
プル、マンジンダー・シン
チャガレ、マルティ
Original Assignee
シプラ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38815026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2010504314(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by シプラ・リミテッド filed Critical シプラ・リミテッド
Publication of JP2010504314A publication Critical patent/JP2010504314A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009528789A 2006-09-22 2007-09-24 リファキシミン Pending JP2010504314A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1520MU2006 2006-09-22
PCT/GB2007/003629 WO2008035109A1 (en) 2006-09-22 2007-09-24 Rifaximin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015203164A Division JP2016065058A (ja) 2006-09-22 2015-10-14 リファキシミン

Publications (1)

Publication Number Publication Date
JP2010504314A true JP2010504314A (ja) 2010-02-12

Family

ID=38815026

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2009528789A Pending JP2010504314A (ja) 2006-09-22 2007-09-24 リファキシミン
JP2015203164A Pending JP2016065058A (ja) 2006-09-22 2015-10-14 リファキシミン
JP2018053934A Pending JP2018127470A (ja) 2006-09-22 2018-03-22 リファキシミン
JP2020072816A Active JP7346353B2 (ja) 2006-09-22 2020-04-15 リファキシミン
JP2021146649A Pending JP2022003038A (ja) 2006-09-22 2021-09-09 リファキシミン
JP2021150675A Pending JP2022003052A (ja) 2006-09-22 2021-09-16 リファキシミン
JP2023028267A Withdrawn JP2023078160A (ja) 2006-09-22 2023-02-27 リファキシミン

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2015203164A Pending JP2016065058A (ja) 2006-09-22 2015-10-14 リファキシミン
JP2018053934A Pending JP2018127470A (ja) 2006-09-22 2018-03-22 リファキシミン
JP2020072816A Active JP7346353B2 (ja) 2006-09-22 2020-04-15 リファキシミン
JP2021146649A Pending JP2022003038A (ja) 2006-09-22 2021-09-09 リファキシミン
JP2021150675A Pending JP2022003052A (ja) 2006-09-22 2021-09-16 リファキシミン
JP2023028267A Withdrawn JP2023078160A (ja) 2006-09-22 2023-02-27 リファキシミン

Country Status (8)

Country Link
US (8) US8633234B2 (https=)
EP (1) EP2069363B1 (https=)
JP (7) JP2010504314A (https=)
KR (2) KR101667534B1 (https=)
AU (1) AU2007298733B2 (https=)
CA (1) CA2663776C (https=)
NZ (1) NZ575550A (https=)
WO (1) WO2008035109A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521273A (ja) * 2010-03-05 2013-06-10 アルファ ワッセルマン ソシエタ ペル アチオニ リファキシミン粉体、その調製方法、及び長期持続効果を得るために有用な前記リファキシミン含有徐放性組成物
JP2014532723A (ja) * 2011-11-02 2014-12-08 サリックス ファーマスーティカルズ，リミテッド 過敏性腸症候群（ｉｂｓ）及び感染症を治療するための方法

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
KR101667534B1 (ko) * 2006-09-22 2016-10-19 씨아이피엘에이 엘티디. 리팍시민
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
UA113275C2 (xx) 2008-02-25 2017-01-10 ζ-ФОРМА РИФАКСИМІНУ І ЇЇ ЗАСТОСУВАННЯ
HUE048293T2 (hu) 2008-10-02 2020-07-28 Salix Pharmaceuticals Ltd Eljárások hepatikus enkefalopátia kezelésére
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
ES2718614T3 (es) 2008-12-10 2019-07-03 Cipla Ltd Complejos de rifaximina
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
WO2011080691A1 (en) * 2009-12-28 2011-07-07 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
IT1399141B1 (it) * 2010-04-02 2013-04-05 Secci Metodo per la preparazione di rifaximina in stato amorfo.
AU2011225810B2 (en) 2010-03-10 2014-11-06 Lupin Limited Rifaximin ready-to-use suspension
CA2802874A1 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
WO2012035544A2 (en) * 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
SG192122A1 (en) * 2011-02-11 2013-08-30 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
WO2012150561A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110983A1 (it) * 2011-05-30 2012-12-01 A M S A Anonima Materie Sint & Affini S P A Amorfo di rifaximina e processo per la sua preparazione
WO2013027227A1 (en) * 2011-07-20 2013-02-28 Ind-Swift Laboratories Limited Novel polymorphic form i of rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CA2876737A1 (en) 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014140995A2 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
CN105142636A (zh) 2013-03-15 2015-12-09 意大利阿尔法韦士曼制药公司 用于治疗阴道感染的利福昔明
EP2983647B1 (en) 2013-04-12 2020-09-09 Alfasigma S.p.A. Nsaid administration and related compositions, methods and systems
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
EP3134415A4 (en) * 2014-04-19 2017-10-25 Granules India Limited An improved process for the preparation of rifamycin derivatives
US10685402B1 (en) 2014-04-25 2020-06-16 State Farm Mutual Automobile Insurance Company Systems and methods for homeowner-directed risk of property damage mitigation
NZ723571A (en) 2014-05-12 2020-02-28 Alfasigma Spa New solvated crystal form of rifaximin, production, compositions and uses thereof
MX381919B (es) * 2014-06-30 2025-03-13 Salix Pharmaceuticals Inc Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
US10353359B1 (en) 2014-10-07 2019-07-16 State Farm Mutual Automobile Insurance Company Systems and methods for managing smart devices based upon electrical usage data
WO2016063289A2 (en) * 2014-10-22 2016-04-28 Strides Arcolab Limited Pharmaceutical tablet compositions comprising rifaximin
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
WO2018178777A1 (en) * 2017-03-31 2018-10-04 Granules India Limited Process for the preparation of rifaximin crystalline form
CN111423456A (zh) * 2020-04-03 2020-07-17 南京昊绿生物科技有限公司 一种利福昔明-d6的合成工艺
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
CN117447487A (zh) * 2022-07-19 2024-01-26 重庆圣华曦药业股份有限公司 一种利福昔明的纯化方法及其在利福昔明片剂中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044823A2 (en) * 2003-11-07 2005-05-19 Alfa Wassermann S.P.A. Polymorphous forms of rifaximin as antibiotics

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089818A (en) 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1294205B1 (it) 1997-07-23 1999-03-24 Farmigea Spa Procedimento per la solubilizzazione in acqua e in veicoli acquosi di sostanze farmacologicamente attive
JPH11246404A (ja) * 1998-03-04 1999-09-14 Taiho Yakuhin Kogyo Kk 吸収を改善した医薬組成物
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
WO2002032459A2 (en) 2000-10-17 2002-04-25 Massachusetts Institute Of Technology Method of increasing the efficacy of antibiotics by complexing with cyclodextrins
AU2005297923B2 (en) * 2004-10-25 2010-12-23 Japan Tobacco Inc. Solid medicinal preparation improved in solubility and stability and process for producing the same
PT1698630E (pt) * 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
US20070082870A1 (en) 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
KR101667534B1 (ko) * 2006-09-22 2016-10-19 씨아이피엘에이 엘티디. 리팍시민
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009137672A1 (en) 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
ES2718614T3 (es) 2008-12-10 2019-07-03 Cipla Ltd Complejos de rifaximina

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044823A2 (en) * 2003-11-07 2005-05-19 Alfa Wassermann S.P.A. Polymorphous forms of rifaximin as antibiotics

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521273A (ja) * 2010-03-05 2013-06-10 アルファ ワッセルマン ソシエタ ペル アチオニ リファキシミン粉体、その調製方法、及び長期持続効果を得るために有用な前記リファキシミン含有徐放性組成物
JP2014532723A (ja) * 2011-11-02 2014-12-08 サリックス ファーマスーティカルズ，リミテッド 過敏性腸症候群（ｉｂｓ）及び感染症を治療するための方法

Also Published As

Publication number Publication date
AU2007298733B2 (en) 2012-11-08
US12109200B2 (en) 2024-10-08
NZ575550A (en) 2011-12-22
KR101667534B1 (ko) 2016-10-19
CA2663776A1 (en) 2008-03-27
US20230116935A1 (en) 2023-04-20
JP2022003052A (ja) 2022-01-11
JP2018127470A (ja) 2018-08-16
KR20090080048A (ko) 2009-07-23
KR101480732B1 (ko) 2015-01-21
US20180235944A1 (en) 2018-08-23
US20200368212A1 (en) 2020-11-26
CA2663776C (en) 2016-01-26
US10702505B2 (en) 2020-07-07
JP2016065058A (ja) 2016-04-28
JP2020128380A (ja) 2020-08-27
US9877953B2 (en) 2018-01-30
JP2022003038A (ja) 2022-01-11
EP2069363B1 (en) 2013-03-20
US8633234B2 (en) 2014-01-21
EP2069363A1 (en) 2009-06-17
KR20140131543A (ko) 2014-11-13
US20160374999A1 (en) 2016-12-29
WO2008035109A1 (en) 2008-03-27
US20150266898A1 (en) 2015-09-24
JP7346353B2 (ja) 2023-09-19
US20140128419A1 (en) 2014-05-08
US20120116071A1 (en) 2012-05-10
US20090312357A1 (en) 2009-12-17
US9403844B2 (en) 2016-08-02
JP2023078160A (ja) 2023-06-06
AU2007298733A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
JP7346353B2 (ja) リファキシミン
CN103539795A (zh) 阿哌沙班的多晶型及其制备方法
WO2018064797A1 (zh) Acp-196的晶型及其制备方法和药物组合物
MX2011007790A (es) Polimorfos de darunavir.
CN111164085B (zh) 瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途
EP3560919A1 (en) Salt of substituted piperidine compound
CN116987070B (zh) 呋喹替尼的共晶、其制备方法、组合物和用途
JP5642766B2 (ja) アデフォビルジピボキシルの新規結晶形及びその製造方法
CN104817557A (zh) 一种盐酸莫西沙星的稳定晶型及其制备方法
JP2009526068A (ja) シクレソニド結晶形
WO2017118633A1 (en) Crystalline form of ticagrelor
CN106496235A (zh) 结晶形态的三唑[4,5‑d]嘧啶化合物及其制备方法和用途
KR20110103051A (ko) 아데포비어 디피복실의 새로운 다형체 및 이의 제조 방법
JP2010285355A (ja) β−ラクタム化合物の安定形結晶の製法
KR20100062929A (ko) 새로운 결정형의 아데포비어 디피복실, 그 조성물 및 이것의 제조방법
HK1077580A1 (en) Methods of making ferric organic compounds

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130304

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130604

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131105

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20131224

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151014